Australia's PharmAust gains on positive result for its motor neurone disease drug
** Shares of PharmAust Ltd PAA.AX gain as much as 7.8% to
A$0.069 - set for best day since Dec. 2, if gains hold
** Biotech co says it completed first cohort of six patients
in its early stage trial of its drug 'monepantel' for motor
neurone disease (MND)
** Says the drug was tolerated by all MND patients at first
dosing level and all six patients have elected to continue on
treatment
** PAA hits its highest level since Dec. 13
** Stock fell 36% YTD in 2022
(Reporting by Ayushman Ojha in Bengaluru)
((Ayushman.ojha@thomsonreuters.com))
Recent news on Winsome Resources
See all newsBrief: Winsome Resources Says 96.87% Total Votes Cast By Co's Shareholders Were In Favour Of Share Scheme Resolution
Brief: Winsome Resources Says Court Approves Convening Of Scheme Meetings
Australia's Winsome Resources rises after Li-FT Power announces buyout
Brief: Winsome Resources Says Li-Ft Power Agrees To Combine
Brief: Winsome Resources Seeks Trading Halt Pending Response To ASX Price Query